Valuation: Quoin Pharmaceuticals, Ltd.

Capitalization 10.7M 9.09M 8.32M 7.85M 14.64M 1.01B 14.77M 98.65M 38.45M 485M 40.13M 39.28M 1.68B P/E ratio 2026 *
-0.77x
P/E ratio 2027 * -1.72x
Enterprise value 10.7M 9.09M 8.32M 7.85M 14.64M 1.01B 14.77M 98.65M 38.45M 485M 40.13M 39.28M 1.68B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
39.18%
Yield 2026 *
-
Yield 2027 * -
1 day-6.91%
1 week-4.51%
Current month-8.49%
1 month-1.00%
3 months-16.95%
6 months-34.18%
Current year-58.91%
1 week 5.81
Extreme 5.81
6.69
1 month 5.2
Extreme 5.2001
6.98
Current year 5.2
Extreme 5.2001
14.49
1 year 5.2
Extreme 5.2001
41.8
3 years 5.01
Extreme 5.01
420
5 years 5.01
Extreme 5.01
70,638.86
10 years 5.01
Extreme 5.01
70,638.86
Manager TitleAgeSince
Chief Operating Officer 57 27/10/2021
Chief Executive Officer 64 27/10/2021
Director of Finance/CFO 43 17/08/2025
Director TitleAgeSince
Director/Board Member - 27/10/2021
Director/Board Member 74 27/10/2021
Director/Board Member 68 27/10/2021
Change 5d. change 1-year change 3-years change Capi.($)
-6.91%-4.51%-5.31%-97.52% 10.7M
-0.66%+0.79%-15.44%-16.46% 43.39B
-1.54%+6.21%+32.29%+22.92% 34.7B
-0.49%+1.67%+238.37%+480.24% 30.15B
+0.04%+13.27%+16.58%-5.85% 29.83B
-2.02%-1.05%+29.45%+33.41% 28.46B
-6.96%+0.55%+424.83%+4,203.98% 14.48B
-3.04%+8.03% - - 14.74B
-0.41%+0.57%+131.18%+115.21% 12.51B
-0.64%+0.54%+5.74%-8.68% 12.29B
Average -2.26%+2.61%+95.30%+525.25% 22.06B
Weighted average by Cap. -1.41%+3.65%+81.79%+376.75%

Financials

2026 *2027 *
Net sales - -
Net income -20.06M -17.04M -15.6M -14.72M -27.46M -1.89B -27.7M -185M -72.13M -910M -75.26M -73.68M -3.14B -34.25M -29.1M -26.63M -25.14M -46.89M -3.23B -47.3M -316M -123M -1.55B -129M -126M -5.36B
Net Debt - -
Logo Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Employees
5
Date Price Change Volume
08/05/26 5.930 $ -6.91% 29,663
07/05/26 6.370 $ -0.93% 22,856
06/05/26 6.430 $ +1.90% 8,355
05/05/26 6.310 $ -0.79% 15,307
04/05/26 6.360 $ +2.42% 6,097
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.930USD
Average target price
29.75USD
Spread / Average Target
+401.69%

Quarterly revenue - Rate of surprise